Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE

Lupus Science and Medicine

Volumn 2, Issue 1, 2015, Pages

  Kennedy, William P ^a   Maciuca, Romeo ^a   Wolslegel, Kristen ^a   Tew, Wei ^a   Abbas, Alexander R ^a   Chaivorapol, Christina ^a   Morimoto, Alyssa ^a   McBride, Jacqueline M ^a   Brunetta, Paul ^a   Richardson, Bruce C ^b   Davis, John C ^a   Behrens, Timothy W ^a   Townsend, Michael J ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CELL NUCLEUS ANTIGEN; INTERFERON; RITUXIMAB; RONTALIZUMAB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIOLOGICAL ACTIVITY; BRITISH ISLES LUPUS ASSESSMENT GROUP ACTIVITY INDEX; CMPK2 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DISEASE ACTIVITY; EOSINOPHIL COUNT; EPSTI GENE; EXTRARENAL LUPUS; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; HERC5 GENE; HUMAN; IMMUNOPATHOGENESIS; INTERFERON SIGNATURE; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFETY OF ESTROGEN IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT; SEROLOGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84949212787     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2014-000080     Document Type: Article

References (30)

1. Koffler D, Agnello V, Thoburn R, et al. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 1971;134:169s-79s.
2. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560-6.
3. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun Rev 2008;7:317-21.
4. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. Exp Rev Pharmacoec Outcomes Res 2011;11:455-68.
5. Wollaston SJ, Farewell VT, Isenberg DA, et al. Defining response in systemic lupus erythematosus: A study by the Systemic Lupus International Collaborating Clinics group. J Rheum 2004;31:2390-4.
6. Ronnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheum 2013;25:248-53.
7. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25:383-92.
8. Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arth Res Ther 2010;12(Suppl 1):S5.
9. Bronson PG, Chaivorapol C, Ortmann W, et al. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immun 2012;24:530-7.
10. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Nat Acad Sci 2003;100:2610-5.
11. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
12. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
13. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-20.
14. Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha. Clin Immunol 2012;143:210-21.
15. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferonpathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:2407-15.
16. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666-76.
17. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
18. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709-16.
19. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-?) in systemic lupus erythematosus patients (ROSE). Ann Rheum Dis 2015. doi: 10.1136/annrheumdis-2014-206090.
20. Bourgon R, Gentleman R, Huber W. Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci 2010;107:9546-51.
21. Ronni T, Matikainen S, Lehtonen A, et al. The proximal interferon-stimulated response elements are essential for interferon responsiveness: A promoter analysis of the antiviral MxA gene. J Interferon Cytokine Res 1998;18:773-81.
22. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001;194:F59-63.
23. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17.
24. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009;227:75-86.
25. Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786-91.
26. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465:937-41.
27. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: A phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21.
28. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66:1583-95.
29. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
30. Bienkowska J, Allaire N, Thai A, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One 2014;9:e112545.